Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll 18F-FDG imaging: pitfalls and artifacts Abouzied MM; Crawford ES; Nabi HAJ Nucl Med Technol 2005[Sep]; 33 (3): 145-55; quiz 162-318F-FDG PET is emerging as a useful tool in the staging and restaging of many malignant neoplasms, such as lymphoma, lung cancer, colorectal cancer, head and neck cancer, breast cancer, and melanoma. To accurately interpret 18F-FDG findings one must be familiar with the normal physiologic distribution of the tracer, frequently encountered physiologic variants, and benign pathologic causes of 18F-FDG uptake that can be confused with a malignant neoplasm. The objectives of this article are to (a) describe the mechanism of 18F-FDG uptake, (b) list the patient preparation and pertinent patient history before 18F-FDG imaging, (c) describe the whole-body physiologic distribution of 18F-FDG, (d) list and discuss normal physiologic variants, and (e) list and discuss benign pathologic causes of 18F-FDG uptake.|*Artifacts[MESH]|Diagnostic Errors/*prevention & control[MESH]|Fluorodeoxyglucose F18/*pharmacokinetics[MESH]|Humans[MESH]|Neoplasms/*diagnostic imaging/*metabolism[MESH]|Organ Specificity[MESH]|Positron-Emission Tomography/*methods[MESH]|Practice Guidelines as Topic[MESH]|Practice Patterns, Physicians'[MESH]|Radiopharmaceuticals/pharmacokinetics[MESH]|Tissue Distribution[MESH] |